Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the “off-label” use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2018-09, Vol.122 (6), p.1028-1035
Main Authors: De Backer, Ole, Pilgrim, Thomas, Simonato, Matheus, Mackensen, G. Burkhard, Fiorina, Claudia, Veulemanns, Verena, Cerillo, Alfredo, Schofer, Joachim, Amabile, Nicolas, Achkouty, Guy, Schäfer, Ulrich, Deutsch, Marcus-André, Sinning, Jan-Malte, Rahman, Mohammed S., Sawaya, Fadi J., Hildick-Smith, David, Hernandez, Jose Maria, Kim, Won-Keun, Lefevre, Thierry, Seiffert, Moritz, Bleiziffer, Sabine, Petronio, Anna Sonia, Van Mieghem, Nicolas, Taramasso, Maurizio, Søndergaard, Lars, Windecker, Stephan, Latib, Azeem, Dvir, Danny
Format: Article
Language:English
Subjects:
Aortic valve
Clinical outcomes
Consortia
Endocarditis
Heart valves
Implantation
Medical personnel
Mortality
Patients
Regurgitation
Risk
Risk groups
Stroke
Success
Surgery
Thorax
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the “off-label” use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2%) underwent transcatheter aortic valve implantation (TAVI) with early generation (43%) or newer generation (57%) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82% vs 47%, p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2018.05.044